349 related articles for article (PubMed ID: 37985748)
21. Role of the gut microbiome in cardiovascular drug response: The potential for clinical application.
Steiner HE; Gee K; Giles J; Knight H; Hurwitz BL; Karnes JH
Pharmacotherapy; 2022 Feb; 42(2):165-176. PubMed ID: 34820870
[TBL] [Abstract][Full Text] [Related]
22. Pharmacomicrobiomics in Pediatric Oncology: The Complex Interplay between Commonly Used Drugs and Gut Microbiome.
Leardini D; Venturelli F; Baccelli F; Cerasi S; Muratore E; Brigidi P; Pession A; Prete A; Masetti R
Int J Mol Sci; 2022 Dec; 23(23):. PubMed ID: 36499714
[TBL] [Abstract][Full Text] [Related]
23. Clinical significance of microbiota changes under the influence of psychotropic drugs. An updated narrative review.
Misera A; Łoniewski I; Palma J; Kulaszyńska M; Czarnecka W; Kaczmarczyk M; Liśkiewicz P; Samochowiec J; Skonieczna-Żydecka K
Front Microbiol; 2023; 14():1125022. PubMed ID: 36937257
[TBL] [Abstract][Full Text] [Related]
24. Drug-microbiota interactions: an emerging priority for precision medicine.
Zhao Q; Chen Y; Huang W; Zhou H; Zhang W
Signal Transduct Target Ther; 2023 Oct; 8(1):386. PubMed ID: 37806986
[TBL] [Abstract][Full Text] [Related]
25. Gut Reactions: Breaking Down Xenobiotic-Microbiome Interactions.
Clarke G; Sandhu KV; Griffin BT; Dinan TG; Cryan JF; Hyland NP
Pharmacol Rev; 2019 Apr; 71(2):198-224. PubMed ID: 30890566
[TBL] [Abstract][Full Text] [Related]
26. Pharmacomicrobiomics: Exploiting the Drug-Microbiota Interactions in Antihypertensive Treatment.
Chen HQ; Gong JY; Xing K; Liu MZ; Ren H; Luo JQ
Front Med (Lausanne); 2021; 8():742394. PubMed ID: 35127738
[TBL] [Abstract][Full Text] [Related]
27. Human Gut Microbiota and Drug Metabolism.
Pant A; Maiti TK; Mahajan D; Das B
Microb Ecol; 2023 Jul; 86(1):97-111. PubMed ID: 35869999
[TBL] [Abstract][Full Text] [Related]
28. Toll-like receptors in the pathogenesis of chemotherapy-induced gastrointestinal toxicity.
Cario E
Curr Opin Support Palliat Care; 2016 Jun; 10(2):157-64. PubMed ID: 26986508
[TBL] [Abstract][Full Text] [Related]
29. The Role of Gut Microbiota in Modulating Tumor Growth and Anticancer Agent Efficacy.
Kim J; Lee HK
Mol Cells; 2021 May; 44(5):356-362. PubMed ID: 33972463
[TBL] [Abstract][Full Text] [Related]
30. The Yin-Yang Pharmacomicrobiomics on Treatment Response in Inflammatory Arthritides: A Narrative Review.
Peretti S; Torracchi S; Russo E; Bonomi F; Fiorentini E; Aoufy KE; Bruni C; Lepri G; Orlandi M; Chimenti MS; Guiducci S; Amedei A; Matucci-Cerinic M; Bellando Randone S
Genes (Basel); 2022 Dec; 14(1):. PubMed ID: 36672830
[TBL] [Abstract][Full Text] [Related]
31. Relationship Between the Gut Microbiome and Systemic Chemotherapy.
Ervin SM; Ramanan SV; Bhatt AP
Dig Dis Sci; 2020 Mar; 65(3):874-884. PubMed ID: 32026181
[TBL] [Abstract][Full Text] [Related]
32. Human Microbiota and Personalized Cancer Treatments: Role of Commensal Microbes in Treatment Outcomes for Cancer Patients.
Gately S
Cancer Treat Res; 2019; 178():253-264. PubMed ID: 31209849
[TBL] [Abstract][Full Text] [Related]
33. Immunogenic cell death: A link between gut microbiota and anticancer effects.
Chen W; Wang S; Wu Y; Shen X; Guo Z; Li Q; Xing D
Microb Pathog; 2020 Apr; 141():103983. PubMed ID: 31954823
[TBL] [Abstract][Full Text] [Related]
34. Microbiome in Immune-Mediated Uveitis.
Rodríguez-Fernández CA; Iglesias MB; de Domingo B; Conde-Pérez K; Vallejo JA; Rodríguez-Martínez L; González-Barcia M; Llorenç V; Mondelo-Garcia C; Poza M; Fernández-Ferreiro A
Int J Mol Sci; 2022 Jun; 23(13):. PubMed ID: 35806031
[TBL] [Abstract][Full Text] [Related]
35. Drug pharmacomicrobiomics and toxicomicrobiomics: from scattered reports to systematic studies of drug-microbiome interactions.
Aziz RK; Hegazy SM; Yasser R; Rizkallah MR; ElRakaiby MT
Expert Opin Drug Metab Toxicol; 2018 Oct; 14(10):1043-1055. PubMed ID: 30269615
[TBL] [Abstract][Full Text] [Related]
36. Gut microbiota-drug interactions in cancer pharmacotherapies: implications for efficacy and adverse effects.
Leigh SJ; Lynch CMK; Bird BRH; Griffin BT; Cryan JF; Clarke G
Expert Opin Drug Metab Toxicol; 2022 Jan; 18(1):5-26. PubMed ID: 35176217
[TBL] [Abstract][Full Text] [Related]
37. Drug Metabolism by the Host and Gut Microbiota: A Partnership or Rivalry?
Swanson HI
Drug Metab Dispos; 2015 Oct; 43(10):1499-504. PubMed ID: 26261284
[TBL] [Abstract][Full Text] [Related]
38. A Review of Gut Microbiota-Derived Metabolites in Tumor Progression and Cancer Therapy.
Yang Q; Wang B; Zheng Q; Li H; Meng X; Zhou F; Zhang L
Adv Sci (Weinh); 2023 May; 10(15):e2207366. PubMed ID: 36951547
[TBL] [Abstract][Full Text] [Related]
39. The role of the microbiome in drug resistance in gastrointestinal cancers.
Garajová I; Balsano R; Wang H; Leonardi F; Giovannetti E; Deng D; Peters GJ
Expert Rev Anticancer Ther; 2021 Feb; 21(2):165-176. PubMed ID: 33115280
[No Abstract] [Full Text] [Related]
40. Auxiliary antitumor effects of fungal proteins from Hericium erinaceus by target on the gut microbiota.
Wang D; Zhu X; Tang X; Li H; Yizhen X; Chen D
J Food Sci; 2020 Jun; 85(6):1872-1890. PubMed ID: 32460371
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
